Maryland Medical Assistance Plan and Health Insurance - Pharmacogenomic Testing - Required Coverage
Hearing (House)
Email me when SB 608 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track SB 608. By continuing you agree to the Terms and Privacy Policy.
Summary
The bill requires the Maryland Medical Assistance program, private insurers, nonprofit health service plans and health maintenance organizations to pay for single‑gene and multigene pharmacogenomic tests when a treating provider orders them for a patient diagnosed with depression or anxiety and the medication under consideration has a known gene‑drug interaction. It also limits prior‑authorization requirements, sets audit and reporting procedures, and imposes penalties for non‑compliance. The goal is to improve medication safety and effectiveness for affected patients.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about SB 608
3 free questions a day, no accountHearings
- Health — Bill HearingHealth · Apr 2, 2026
- Assembly Health CommitteeAssembly Health Committee · Apr 2, 2026
- Finance — Bill HearingFinance · Mar 4, 2026
History
- Hearing 4/02 at 1:00 p.m.
- Referred Health
- Third Reading Passed
- Second Reading Passed with Amendments
- Favorable with Amendments Report by Finance
- Favorable with Amendments {
- Hearing 3/04 at 1:00 p.m.
- First Reading Finance
Sponsors
- Mautz · sponsor
Similar bills in other states
Loading the map of where bills like this one were filed.
Topics
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when SB 608 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track SB 608 freeOr ask your AI assistant about SB 608 directly:
Add to Claude, ChatGPT or Cursor